<DOC>
	<DOCNO>NCT00497328</DOCNO>
	<brief_summary>This randomise controlled trial investigate efficacy preventive regimen hydration high dose oral N-acetylcysteine intravenous sodium bicarbonate pretreatment patient stable advanced renal insufficiency ( CKD stage 3 4 : GFR 15-60ml/min/1.73m2 calculate Modification Diet Renal Disease Study equation ( MDRD formula ) ) undergo elective percutaneous coronary intervention ( PCI ) .</brief_summary>
	<brief_title>COmbined N-acetylcysteine Bicarbonate PCI To Reduce Adverse Side Effect contrasT</brief_title>
	<detailed_description>OBJECTIVES Primary Objective To investigate whether combination therapy high dose oral N-acetylcysteine NAC ) intravenous ( IV ) sodium bicarbonate reduce incidence contrast induce nephropathy ( CIN ) patient baseline renal impairment undergo elective percutaneous coronary intervention ( PCI ) . Secondary Objective - To compare effectiveness prevention CIN either NAC sodium bicarbonate arm therapy . - Maximum change serum creatinine level within 30 day - Difference hospital stay group - Need hemodialysis within 30 day - 30 day mortality - Maximum change GFR within 30 day - Peak creatinine level within 48 hour 30 day TRIAL DESIGN Trial Design : Randomized , open label , active control , multi-center , efficacy study Trial Population : 630 Recruitment duration : 18 month Trial Sites : - National University Hospital ( Singapore ) - Sarawak General Hospital ( Malaysia ) - Institue Jantung Negara ( Malaysia ) - Nanjing First Hospital ( China ) - Guangdong Provincial Cardiovascular Institute ( China ) All patient baseline creatinine clearance 15 60 mL/min undergo cardiac catheterization either electively follow acute coronary syndrome approach participate study . After write informed consent sign , patient screen eligibility criteira . Only eligible patient randomly assign one three group 1:1:1 ratio . - NAC : Infusion sodium chloride oral NAC - SOB : Infusion sodium bicarbonate - COM : Infusion sodium bicarbonate oral NAC Inclusion Criteria - Age &gt; 21 year - Glomerular Filtration Rate ( GFR ) 15-60ml/min calculated MDRD formula - Scheduled undergo elective PCI - Able receive 12 hour pre-hydration - Written inform consent Exclusion Criteria : - GFR le 15ml/min patient diagnosed end stage renal failure - Increase serum creatinine level &gt; 0.5mg/dl 44umol/l previous 24 hour - Preexisting dialysis - Pulmonary edema moderate severe congestive heart failure ( New York Heart Association [ NYHA ] III-IV ) - Patient unable withstand fluid load hemodynamics compromise - Uncontrolled hypertension ( untreated systolic blood pressure &gt; 160 mmHg , diastolic blood pressure &gt; 100mmHg . ) - Emergency cardiac catheterization ( i.e . patient present ST segment elevation myocardial infarction undergo primary angioplasty ) - Recent exposure radiographic contrast ( within two day study ) . - Allergic radio-contrast - Administration sodium bicarbonate solution NAC within 48 hour PCI . - Patient unable give consent - Clinically vulnerable condition require continuous fluid therapy e.g . severe sepsis - Use NSAID , aminoglycocide , cyclosporin , cysplatin within 48 hour prior PCI throughout study duration TREATMENT SCHEDULE Treatment Groups After randomisation , patient receive one follow treatment : N-acetylcysteine Group ( NAC ) - Intravenous infusion 154mEq/L sodium chloride ( 0.9 % normal saline ) rate 1mL/kg/hour 12 hour till 6 hour cardiac catheterization - Oral NAC 1200mg dissolve 250ml water twice day day day procedure ( total 6 dos ) Sodium Bicarbonate Group ( SOB ) - Intravenous infusion154meq/L sodium bicarbonate 5 % dextrose water rate 3 mL/kg/hour 1 hour immediately radiocontrast injection . For patient weigh 110 kg , initial fluid bolus drip limited dos administer patient weigh 110 kg . - Intravenous infusion154meq/L sodium bicarbonate 5 % dextrose water rate 1 mL/kg/hour contrast exposure 6 hour procedure Combination Group ( COM : NAC SOB ) - Intravenous infusion 154 meq/l sodium bicarbonate rate 3ml/kg/hour 1 hour cardiac catheterization 1 ml/kg/hour till 6 hour procedure - Oral NAC 1200mg dissolve 250ml water twice day day day procedure ( total 6 dos ) . All patient monitor regularly pulmonary congestion hemodynamics compromise hourly PCI 6 hour every 4 hour thereafter 24 hour . Trial Participation Eligible subject enrol study 30 day . Assessments do Day 1,2 3 ( 48 hour PCI ) end study visit Day 30 . Contrast use non-ionic low osmolality type ( iohexol , iopamidol , ioversol , iopromide ) . If Day 3 serum creatinine level increase &gt; 25 % baseline level ( i.e.development CIN ) , patient continune monitor week discretion investigator serum creatinine level improve CIN resolve . Treatment Modification All therapy discontinue adverse-effects cardiac failure pulmonary congestion develop , although anticipate low event occurrence rate . CONCOMITANT MEDICATION Use nonsteroidal anti-inflammatory drug ( NSAID ) , aminoglycocide , cyclosporin , cysplatin allow within 48 hour prior PCI throughout study duration . Metformin withhold 48 hour 48 hour PCI . ACE inhibitor continue discretion doctor charge . Concomitant medication treatment receive study must report concomitant medication case report form provide . Study End Points Statistical Analysis The primary outcome measure development CIN , define increase serum creatinine 25 % within 48 hour PCI ( efficacy parameter ) . Post-contrast creatinine assess morning day 1 2 . The high serum creatinine post-contrast day 1 2 used calculate change serum creatinine . Trial Size Based previous data1,2,4 , assume development CIN 15 % NAC , 15 % SOB 5 % COM . A group sample size 210 patient would require detect statistically significant difference power 90 % two-tailed test size 5 % COM either SOB NAC ; give total 630 patient Final Analysis Analysis intention-to-treat . For efficacy parameter , comparison make COM average SOB NAC ( primary analysis ) . Pair-wise comparison may also make COM SOB NAC . Tests significance conduct use chi-squared test primary endpoint . Relative risk 95 % confidence interval present primary analysis , although power demonstrate equivalence , SOB NAC . Further analysis conduct use logistic regression adjust potential risk factor . For binary saftey outcome ( need hemodialysis within 30 day 30-day mortality ) adverse event , chi-squared test Fisher 's exact test use . T-tests Wilcoxon-signed rank test use continuous saftey outcome ( maximum change serum creatinine level within 30 day , length hospital stay , maximum change GFR within 30 day peak creatinine level within 48 hour 30 day ) . A two-tailed significance level p &lt; 0.05 use endpoint final analysis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Age &gt; 21 year Glomerular Filtration Rate ( GFR ) 1560ml/min calculate MDRD formula Scheduled undergo elective PCI Able receive 12 hour prehydration Written inform consent GFR le 15ml/min patient diagnosed end stage renal failure Increase serum creatinine level &gt; 0.5mg/dl 44umol/l previous 24 hour Preexisting dialysis Pulmonary edema moderate severe congestive heart failure ( New York Heart Association [ NYHA ] IIIIV ) Patient unable withstand fluid load hemodynamics compromise Uncontrolled hypertension ( untreated systolic blood pressure &gt; 160 mmHg , diastolic blood pressure &gt; 100mmHg . ) Emergency cardiac catheterization ( i.e . patient present ST segment elevation myocardial infarction undergo primary angioplasty ) Recent exposure radiographic contrast ( within two day study ) . Allergic radiocontrast Administration sodium bicarbonate solution NAC within 48 hour PCI . Patient unable give consent Clinically vulnerable condition require continuous fluid therapy e.g . severe sepsis Use NSAID , aminoglycocide , cyclosporin , cysplatin within 48 hour prior PCI throughout study duration</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>contrast induce nephropathy</keyword>
</DOC>